Day: July 9, 2020

VANCOUVER and MINNEAPOLIS, July 09, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device (“Reducer”) at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in the U.S. for the treatment of patients suffering from refractory angina pectoris despite guideline directed medical therapy, who are unsuitable for revascularization by coronary artery bypass grafting (CABG) or by percutaneous coronary intervention (PCI).“Today’s announcement marks a significant milestone for Neovasc, as...

WASHINGTON, July 09, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it will release financial results for the second quarter ended June 30, 2020, before the New York market opens on Thursday, July 30, 2020.A conference call will be held to discuss these financial results on Thursday, July 30, 2020, at 9:00 a.m. Eastern Time and will be hosted by senior management.The conference call will be simulcast live on the Internet and can be accessed by logging onto the Company’s investor relations website. A replay of the webcast will be available on the Company’s investor relations website for 90 days.About FTI ConsultingFTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political...

DALLAS, July 09, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), a fully-reporting, early stage, emerging biotech company focused on aerosol delivery of cannabinoids in the legal hemp and cannabis space using Metered Dose Inhalers (MDIs), announced today that RTSL has received an additional commitment of 150,000 units under a 100,000 unit wholesale order of its Rxoid™ brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream.Donal R. Schmidt, Jr., Chairman and CEO stated, “Our customer that specializes in sales directly to health practitioners has increased their commitment from 100,000 to 250,000 units. The primary reason given was the quality and relief their clients’ patients were receiving from our product. Undoubtedly, our...

NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael Amoroso as Senior Vice President and Chief Commercial Officer (CCO), effective immediately. Mr. Amoroso brings to Abeona over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries, most recently as Senior Vice President and Head of Worldwide Commercial, Cell Therapy at Kite, a Gilead Company.Mr. Amoroso will have overall responsibility for building the Company’s commercial organization, developing the commercialization strategy for EB-101, its autologous, gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) and its lead product candidate, as well as...

NEW YORK, July 09, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, Video Conferencing and Virtual Events, is pleased to announce that NexTech has filed to uplist its stock to the Nasdaq Capital Market.Evan Gappelberg, CEO of NexTech comments, “We have worked very hard to be able to meet the requirements for Nasdaq and believe that we check all the boxes. Our plan to move to a national exchange reflects our capital raising success, as well as the success and momentum in growing our video conferencing software platform InfernoAR and augmented reality business. We believe that listing on Nasdaq will help broaden our shareholder base, increase appeal to institutional investors, indexes and ETF’s and provide shareholders with better liquidity.”Kashif...

TORONTO, July 09, 2020 (GLOBE NEWSWIRE) — CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has launched the first in a series of monthly medical reports derived from real-world clinical treatments on a variety of healthcare conditions and modalities across the United States, Canada and United Kingdom.The Company currently monitors, assesses, and treats over 100,000 patients in the US, and partners with clinical groups in Canada and the UK to help unlock the power of clinical data. Using proprietary technology at the point of care, the Company analyzes this information to support patients and clinicians understand what therapies work versus non-effective treatments. Routine access to this data enables patients and clinicians to better optimize treatment plans to achieve goals and overall health outcomes.“Since developing...

GREENWICH, Conn., July 09, 2020 (GLOBE NEWSWIRE) —  XPO Logistics, Inc. (NYSE: XPO), a top ten global provider of transportation and logistics solutions, has been named by Gartner, Inc. as a Leader in its Magic Quadrant for Third-Party Logistics, Worldwide. This marks the second time the global advisory company has recognized XPO as a global Leader based on ability to execute and completeness of vision.Troy Cooper, president of XPO Logistics, said, “We’re gratified to once again be recognized by Gartner as a Leader in the Magic Quadrant for Third-Party Logistics, Worldwide. XPO is a service business, and every metric comes down to people. I’m proud of our employees for providing essential services to keep supply chains moving – particularly this year during the pandemic. The caliber of our team is a major reason why customers...

SAN ANTONIO, July 09, 2020 (GLOBE NEWSWIRE) — MIRAGE ENERGY CORPORATION, www.mirageenergycorp.com (OTC Pink: MRGE), announces it has signed a new agreement with NORTHERN HEMISPHERE LOGISTICS to increase its participation in the development of Northern Hemisphere’s Isthmus Corridor Project. The signing of this new agreement gives Mirage the right to participate for 50% of the project, an increase from 30% in the original agreement announced on March 16, 2020. The total estimated cost for the project is $2.0 Billion USD.The Isthmus Corridor project consists of a series of pipelines and storage facilities in Mexico connecting the Port of Pajaritos on the Gulf of Mexico side to Salina Cruz on the Pacific side. The pipelines will provide a faster, more economical means of delivering crude oil and refined products from the U.S. to Asia,...

TORONTO, July 09, 2020 (GLOBE NEWSWIRE) — Barrick will release its Q2 2020 results on Monday, August 10, 2020.  Due to the Covid-19 pandemic, president and CEO Mark Bristow will host an interactive webinar on the results at 11:00 EDT, instead of a live presentation.  The webinar will be linked to a conference call.  Participants will be able to ask questions.The company will release its preliminary production and sales information for Q2 2020 on Thursday, July 16, 2020.Release of Q2 preliminary production and sales informationJuly 16, 07:00 EDT / 11:00 UTCQ2 Results release August 10, 06:00 EDT / 10:00 UTCQ2 Results webinar August 10, 11:00 EDT / 15:00 UTC Go to the webinarConference call linked to webinar August 10, 11:00 EDT / 15:00 UTCUS/Canada (toll-free), 1 800 319 4610UK (toll-free), 0808 101 2791International (toll), +1 416...

Houston, Texas and Tuebingen, Germany, July 09, 2020 (GLOBE NEWSWIRE) —Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced changes to its Board of Directors in conjunction with its recent listing on NASDAQ. Michael Atieh, Paul Carter, Heather Mason and Adam Stone will join the Company’s board as new members. Christof Hettich, L.L.D. will remain a Board Member and Peter Chambré will continue to serve as the Chairman of the Board. Collectively, this group of Directors brings a range of experience and expertise which will be invaluable to Immatics’ continued progress as a leader in T cell receptor (TCR)-based therapeutics.Peter Chambré, Chairman...